Integrin alpha V beta 8

Integrin alpha V beta 8

Integrin alpha V beta 8 Informations sur la molécule

Molecule Name
integrin alpha V/beta 8
Alias de la molécule
Integrin alpha V beta 8,ITGAV&ITGB8
Drug Development Progress
Nombre de médicaments cliniques3
Nombre de médicaments commercialisés0
Phase de R&D la plus avancéePhase 2 Clinical
Alias de la cible
alphavbeta8 integrin
Contexte de la molécule
Integrin alpha V beta 8 (ITGAV & ITGB8 or ITGAVB8) is expressed in yolk sac, placenta, brain perivascular astrocytes, Schwann cells, renal glomerular mesangial cells and pulmonary epithelial cells. Unlike other alpha V integrins, ITGAVB8 does not appear to assume different activation states, and the cytoplasmic tail does not connect to the cytoskeleton. It binds ligands containing an RGD motif, including vitronectin, fibrin and the latency associated peptide (LAP) of the latent TGF-beta complex. High affinity binding of alpha V beta 8 to LAP allows proteolytic cleavage by MT1-MMP, which releases active TGF-beta. This mechanism differs from that of alpha V beta 6, the other alpha V integrin which can activate TGF-beta from latency through non-proteolytic mechanisms. Downstream effects of TGF-beta activation include control of cell growth and associated vascularization.

Integrin alpha V beta 8 Liste de produits

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
NesvategrastSF-0166; OTT-166(OcuTerra Therapeutics)Phase 2 ClinicalOcuTerra Therapeutics Inc, Scifluor Life Sciences Inc
Diabetic macular oedema; Diabetic Retinopathy; Macular Degeneration
Details
CRB-601CRB-601Phase 2 ClinicalCorbus Pharmaceuticals Holdings Inc, Uc San Francisco
Solid tumours
Details
PLN-101095PLN-101095Phase 1 ClinicalPliant Therapeutics Inc
Solid tumours
Details